Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview

Author:

Lang Damanpreet K.1ORCID,Kaur Rajwinder1ORCID,Arora Rashmi1ORCID,Saini Balraj1ORCID,Arora Sandeep1ORCID

Affiliation:

1. Chitkara College of Pharmacy, Chitkara University, Punjab, India

Abstract

Background: Cancer is spreading all over the world, and it is becoming the leading cause of major deaths. Today’s most difficult task for every researcher is to invent a new drug that can treat cancer with minimal side effects. Many factors, including pollution, modern lifestyle and food habits, exposure to oncogenic agents or radiations, enhanced industrialization, etc. can cause cancer. Treatment of cancer is done by various methods that include chemotherapy, radiotherapy, surgery and immunotherapy in combination or singly along with kinase inhibitors. Most of the anti-cancer drugs use the concept of kinase inhibition. Objective: The number of drugs being used in chemotherapy has heterocycles as their basic structure in spite of various side effects. Medicinal chemists are focusing on nitrogen-containing heterocyclic compounds like pyrrole, pyrrolidine, pyridine, imidazole, pyrimidines, pyrazole, indole, quinoline, oxadiazole, azole, benzimidazole, etc. as the key building blocks to develop active biological compounds. The aim of this study is to attempt to compile a dataset of nitrogen-containing heterocyclic anti-cancer drugs. Methods: We adopted a structural search on notorious journal publication websites and electronic databases such as Bentham Science, Science Direct, PubMed, Scopus, USFDA, etc. for the collection of peer-reviewed research and review articles for the present review. The quality papers were retrieved, studied, categorized into different sections, analyzed and used for article writing. Conclusion: As per FDA databases, nitrogen-based heterocycles in the drug design are almost 60% of unique small-molecule drugs. Some of the nitrogen-containing heterocyclic anti-cancer drugs are Axitinib, Bosutinib, Cediranib, Dasatanib (Sprycel®), Erlotinib (Tarceva®), Gefitinib (Iressa®), Imatinib (Gleevec®), Lapatinib (Tykerb ®), Linifanib, Sorafenib (Nexavar®), Sunitinib (Sutent®), Tivozanib, etc. In the present review, we shall focus on the overview of nitrogen-containing heterocyclic active compounds as anti-cancer agents.

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Pharmacology,Molecular Medicine

Reference135 articles.

1. Torre L.A.; Bray F.; Siegel R.L.; Ferlay J.; Lortet-Tieulent J.; Jemal A.; Global cancer statistics, 2012. CA Cancer J Clin 2015,65(2),87-108

2. Torre L.A.; Islami F.; Siegel R.L.; Ward E.M.; Jemal A.; Global cancer in women: Burden and trends. Cancer epidemiology. Biomarkers Prevent 2017,26(4),444-457

3. Rang H.P.; Dale M.M.; Ritter J.M.; Moore P.K.; Pharmacology 2003

4. Williams D.A.; Lemke T.L.; Foye’s Principle of Medicinal Chemistry 2002

5. IUPAC Gold Book-Heterocyclic Compounds; ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://goldbook.iupac.org/H02798.html">http://goldbook. iupac.org/H02798.html [Accessed on: 26 May 2015]

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3